EP0863885A2 - Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease - Google Patents

Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease

Info

Publication number
EP0863885A2
EP0863885A2 EP96943497A EP96943497A EP0863885A2 EP 0863885 A2 EP0863885 A2 EP 0863885A2 EP 96943497 A EP96943497 A EP 96943497A EP 96943497 A EP96943497 A EP 96943497A EP 0863885 A2 EP0863885 A2 EP 0863885A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
aryl
hydroxycarboxamide
oxa
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96943497A
Other languages
German (de)
English (en)
Inventor
Chu-Biao Xue
Robert Joseph Cherney
Carl Peter Decicco
William Frank Degrado
Xiaohua He
Carl Nicolas Hodge
Irina Cipora Jacobson
Ronald Louis Magolda
Elizabeth Catherine Arner
Jingwu Duan
David J. Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of EP0863885A2 publication Critical patent/EP0863885A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to macrocyclic molecules which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF) , pharmaceutical preparations containing them and to their use as pharmaceutical agents.
  • metalloproteinases including aggrecanase
  • TNF tumor necrosis factor
  • the compounds are inhibitors of metalloproteinases involved in tissue degradation and inhibitors of the release of tumor necrosis factor.
  • MP metalloproteinases
  • connective tissue including proteoglycan and collagen
  • proteoglycan and collagen leading to resorption of the extracellular matrix.
  • pathological conditions such as rheumatoid and osteoarth ⁇ tis, corneal, epidermal or gastric ulceration; tumor metastasis or invasion; periodontal disease and bone disease.
  • these catabolic enzymes are tightly regulated at the level of their synthesis as well as at their level of extracellular activity through the action of specific inhibitors, such as alpha-2-macroglobulms and TIMP (tissue inhibitor of metalloprotemase) , which form inactive complexes with the MP's.
  • Osteo- and Rheumatoid Arthritis are destructive diseases of articular cartilage characterized by localized erosion of the cartilage surface. Findings have shown that articular cartilage from the femoral heads of patients with OA, for example, had a reduced incorporation of radiolabeled sulfate over controls, suggesting that there must be an enhanced rate of cartilage degradation in OA (Mankin et al . J. Bone Joint Surg. 52A, 1970, 424-434) .
  • aggrecanase (a newly identified metalloprotemase enzymatic activity) has been identified that provides the specific cleavage product of proteoglycan, found in RA and OA patients (Lohmander L.S. et al. Arthritis Rheum. 36, 1993, 1214-22) .
  • MP metalloproteinases
  • This invention describes macrocyclic molecules that inhibit aggrecanase and other metalloproteinases. These novel molecules are provided as cartilage protecting therapeutics. The inhibiton of aggrecanase and other metalloproteinases by these novel molecules prevent the degradation of cartilage by these enzymes, thereby alleviating the pathological conditions of osteo- and rheumatoid arthritis.
  • Tumor necrosis factor is a cell associated cytokme that is processed from a 26kd precursor form to a 17kd active form.
  • TNF has been shown to be a primary mediator humans and in animals, of inflammation, fever, and acute phase responses, similar to those observed during acute infection and shock. Excess TNF has been shown to be lethal.
  • autoimmune diseases such as rheumatoid arthritis (Feldman et al, Lancet, 1994, 344, 1105) and non-msulm dependent diabetes melitus. (Lohmander L.S. et al. Arthritis Rheum. 36, 1993, 1214-22) and Crohn's disease (Macdonald T. et al. Clin. Exp. Immunol. 81, 1990, 301) .
  • TNF-C matrix metalloprotemase or family of metalloproteinases
  • MP's are capable of cleaving TNF from its inactive to active form.
  • This invention describes macrocyclic molecules that inhibit this conversion and hence the secretion of active TNF- ⁇ from cells.
  • novel molecules provide a means of mechanism based therapeutic intervention for diseases including but not restricted to septic shock, haemodynamic shock, sepsis syndrom, post lschaemic reperfusion iury, malaria, Crohn's disease, inflammatory bowel diseases, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic diseases, cachexia, graft rejection, cancer, diseases involving angiogenesis, autoimmune diseases, skin inflammatory diseases, rheumatoid arthritis, multiple sclerosis, radiation damage, hyperoxic alveolar injury, HIV and non-insulin dependent diabetes melitus.
  • diseases including but not restricted to septic shock, haemodynamic shock, sepsis syndrom, post lschaemic reperfusion iury, malaria, Crohn's disease, inflammatory bowel diseases, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic diseases, cachexia, graft rejection
  • AA is an ammo acid, as inhibitors of matrix etallprotemase mediated diseases.
  • W095/09841 describes compounds that are hydroxamic acid derivatives and are inhibitors of cytokme production.
  • GB 2 268 934 A and WO 94/24140 claim hydroxamate inhibitors of MMPs as inhibitors of TNF production.
  • the compounds of the current invention act as inhibitors of MMPs, in particular aggrecanase and TNF-C, thereby preventing cartilage loss and destruction and inflammatory disorders involving TNF.
  • MMPs in particular aggrecanase and TNF-C
  • the hydroxamic and carboxylic acids and derivatives are cyclic, and thus non- peptide nature, which offers a distinct advantage over existing inhibitors because they have superior pharmacokinetic parameters.
  • a selection of these molecules are water soluble and are orally bioavailable.
  • This invention provides novel hydroxamic acids and carboxylic acids and derivatives thereof of formula (I) (described below) which are useful as inhibitors of metalloproteinases, such as aggrecanase and TNF-C.
  • the present invention also includes pharmaceutical compositions comprising such compounds of formula (I) and methods of using such compounds for the treatment of arthritis and other inflammatory disorders as described previously, m a patient.
  • kits comprising one or more containers containing pharmaceutical dosage units comprising a compound of formula (I), for the treatment of arthritis and other inflammatory disorders as described previously, .
  • the present invention also includes methods of inhibiting metalloproteinases, such as aggrecanase and TNF- C, and for the treatment of arthritis by administering a compound of formula (I) combination with one or more second therapeutic agents selected from other inhibitors of metalloproteinases, such as aggrecanase and TNF-C and/or therapeutic agents for the treatment of arthritis and inflammation.
  • This invention provides novel hydroxamic acids and carboxylic acids and derivatives thereof of formula (I) (described below) which are useful as inhibitors of metalloproteinases, such as aggrecanase and TNF-C.
  • the present invention also includes pharmaceutical compositions comprising such compounds of formula (I) and methods of using such compounds for the treatment of arthritis and other inflammatory disorders as described previously, a patient.
  • kits comprising one or more containers containing pharmaceutical dosage units comprising a compound of formula (I), for the treatment of arthritis and other inflammatory disorders as described previously.
  • the present invention also includes methods of inhibiting metalloproteinases, such as aggrecanase and tumor necrosis factor alpha, and for the treatment of arthritis by administering a compound of formula (I) combination with one or more second therapeutic agents selected from other inhibitors of metalloproteinases, such as aggrecanase and tumor necrosis factor alpha and/or therapeutic agents for the treatment of arthritis and inflammation.
  • metalloproteinases such as aggrecanase and tumor necrosis factor alpha
  • U is selected from: -C0 2 H, -CONHOH, -CONHOR 11 , -SH, -NH-
  • R 1 is selected from: H,
  • R 2 is selected from H, -C0 2 R 5 , -CONR 6 R 5 , -CONR 6 (OR 5 ), -alkyl, -alkylaryl, -alkylheteroaryl, -alkylheterocyclic, -aryl, -heteroaryl or -heterocyclic which is substituted with one or more substituents selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, (such as phenoxy) , amino, mono-alkylammo, di- alkylammo, acylammo (such as acetamido and benzamido) , arylammo, guanidmo, N-methyl imidazolyl, imidazolyl, mdolyl, mercapto, lower alkylthio, arylthio (such as phenylthio) , carboxy, sulfonamido, carboxamido,
  • R 3 is selected from:
  • R 2 and R 3 can form a 3 to 8 membered saturated, unsaturated, aryl, heteroaryl or heterocyclic ring;
  • R 4 is selected from:
  • R 5 is selected from:
  • R 7 R 8 m -substituted heterocyclic , wherein the substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylamino, acylammo, thio, thioalkyl, carboxy, carboxamido or aryl;
  • R 6 is selected from:
  • R 5 and R 6 may form a 3 to 8 membered ring optionally unsaturated containing from 1 to 3 heteroatoms selected from -0, -NR 6 , -S(0)p, or an acyl group, optionally fused to an aryl ring;
  • R 7 and R 8 may be selected independently from:
  • substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylammo, thio, thioalkyl, carboxy, carboamido or aryl, optionally containing -0-, -S(0)p, -NR 6 , optionally fused to a substituted aryl ring, wherein the substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylammo, thio, thioalkyl, carboxy, carboxamido or aryl;
  • R 9 is H, alkyl, cycloalkyl 5 or 6 membered ring optionally containing from 1 to 2 N, 0 or S(0)p, optionally substituted with -OH, -0- (Ci-C ⁇ )alkyl, -O-acyl-alkyl, NHR 10 , or aryl;
  • R 10 is H or an optionally substituted alkyl group
  • R 11 is hydrogen, alkyl of from 1 to 10 C atoms which include branched, cyclic and unsaturated alkyl groups, substituted alkyl wherein the substituent is selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, such as phenoxy, amino, di-alkylammo, acylammo such as acetamido and benzamido, arylammo, guanidmo, imidazolyl, dolyl, mercapto, alkylthio, arylthio (such as phenylthio) carboxy, carboxamido, carbo-alkoxy, or sulfonamide,
  • R lla is H, -S0 2 -C ⁇ -C 6 -alkyl, -S0 2 -Ci-C 6 -alkyl- substituted aryl, -S0 -aryl, -S0 2 -substituted heteroaryl, -COR 9 , -C0 2 t-Bu, -C0 Bn, or -alkyl- substituted aryl wherein the substituent is selected from: hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, amino, mono-alkylamino, di-alkylamino, acylamino, thio, thioalkyl, carboxy, carboxamido or aryl;
  • R 12 is selected from: H, aryl, (Ci to C10)alkyl-, aryl (Ci to C6)alkyl-, C3 to C11 cycloalkyl, C3 to C10 alkylcarbonyloxyalkyl, C3 to C10 alkoxycarbonyloxyalkyl, C2 to C10 alkoxycarbonyl, C5 to C10 cycloalkylcarbonyloxyalkyl, C5 to C10 cycloalkoxycarbonyloxyalkyl, C5 to C10 eyeloalkoxycar ony1, aryloxycarbonyl, aryloxycarbonyloxy(Ci to Cg alkyl)-, arylcarbonyloxy(C ⁇ to Ce alkyl)-,
  • R 13 is H or C1-C4 linear alkyl
  • R 15 is selected from:
  • R 16 is C1-C4 alkyl, benzyl, or phenyl
  • R 17 and R 17a is independently selected from: H, C1-C10 alkyl,C2-C6 alkenyl, C4-C11 cycloalkylalkyl, and aryKCi-Ce alkyl) ;
  • A can be absent, -(CHR 6 ) m -, -0(CHR 6 ) m -,
  • B can be a bond or selected from -NH-, -NR 11 -, - NR ll - -0- , -S(0)p- (C ⁇ -C 6 )alkyl-NH- (C ⁇ -C 6 ) alkyl- , (Ci-CeJalkyl-NR 11 - (C ⁇ -C 6 )alky-, -C ⁇ -C 6 -NH-aryl-, -0- (C ⁇ -C 6 )alkyl-, - (Ci-C 6 )alkyl-0-aryl-, -S- (C ⁇ -C 6 )alkyl-, - (C ⁇ -C 6 ) alkyl-S-aryl- , - (C ⁇ -C 6 ) alkyl-, - (C ⁇ -C 6 ) alkenyl- , - (C ⁇ -C 6 )alkyn ⁇ l-, -C0NH-, -CONR 11 , -NHCO-, -
  • D can be absent or an alkyl from 1 to 10 carbon atoms optionally containing 0, S or NR 6 , which include branched and cyclic and unsaturated alkyl groups and aryl C ⁇ -C 6 alkyl-;
  • p can be 0, 1 or 2;
  • n is an integer from 0 to 5;
  • n is an integer from 1 to 5;
  • W is -0-, -S(0)p- or -NR 10 -;
  • Y is selected from: -CONR 10 -, -NR 10 CO-, -SO2NR 10 -, -NR 10 ⁇ O 2 -, a peptide bond mimic, a 5 membered heterocyclic ring saturated, unsaturated or partially unsaturated containing from 1 to 4 heteroatoms selected from N,0 or S,
  • X is selected from CH , NH, NR 5 , S(0)p, or 0;
  • U is selected from; -C0 2 H, -CONHOH, -CONHOR 11 , -SH, -NH-
  • Z is selected from: N or CH;
  • R 1 , R 4 , R 6 , R 11 , R lla , R 12 , R l3 , R 14 , R 15 , R 16 , R 17 R 17a , A, B, C, are as specified previously in Formula I and defined as stable compounds;
  • Preferred compounds of the present invention are compounds of formula I where;
  • U is selected from; -CONHOH, -CONHOR 11 , N(OH)COR 11 ,
  • R 1 is selected from: H,
  • alkyl of from 1 to 20 carbon atoms which include branched, cyclic and unsaturated alkyl groups, substituted alkyl wherein the substituent is selected from; hydrogen, halo, hydroxy, alkoxy, aryloxy, (such as phenoxy) , ammo, mono- alkylammo, di-alkylammo, acylammo (such as acetamido and benzamido) , arylammo, guamdmo, N- methyl imidazolyl, imidazolyl, mdolyl, mercapto, alkylthio, arylthio (such as phenylthio) , carboxy, carboxamido, carbo alkoxy, or sulfonamido,
  • substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylamino, thio, thioalkyl, carboxy, carboamido or aryl;
  • R 2 is selected from H, -C0 2 R 5 , -C0NR 6 R 5 , -CONR 6 (OR 5 ), -alkyl, -alkylaryl, -alkylheteroaryl, -alkylheterocyclic, -aryl, -heteroaryl or -heterocyclic which is substituted with one or more substituents selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, (such as phenoxy) , ammo, mono-alkylammo, di- alkylamino, acylamino (such as acetamido and benzamido) , arylamino, guanidino, N-methyl imidazolyl, imidazolyl, dolyl, mercapto, lower alkylthio, arylthio (such as phenylthio) , carboxy, sulfonamido, carboxamido, or
  • R 3 is selected from
  • R 2 and R 3 can form a 3 to 6 membered saturated, unsaturated, aryl, heteroaryl or heterocyclic ring;
  • R 4 is selected from:
  • R 5 is selected from:
  • R 6 is selected from:
  • R 5 and R 6 may form a 3 to 8 membered ring optionally unsaturated containing from 1 to 3 heteroatoms selected from -O, -NR 6 , -S(0)p, or an acyl group, optionally fused to an aryl ring;
  • R 7 and R 8 may be selected independently from:
  • substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylammo, thio, thioalkyl, carboxy, carboamido or aryl, optionally containing -0-, -S(0)p, -NR 6 , optionally fused to a substituted aryl ring, wherein the substituent is selected from; hydrogen, C 2 .-C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylammo, thio, thioalkyl, carboxy, carboxamido or aryl;
  • R 9 is H, alkyl, cycloalkyl, 5 or 6 membered ring optionally containing from 1 to 2 N, 0 or S(0)p, optionally substituted with -OH, -0- (Ci-C ⁇ )alkyl, -O-acyl-alkyl, NHR 10 , or aryl;
  • R 10 is H or an optionally substituted alkyl group,-
  • R 11 is hydrogen, alkyl of from 1 to 10 C atoms which include branched, cyclic and unsaturated alkyl groups, substituted alkyl wherein the substituent is selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, such as phenoxy, ammo, di-alkylammo, acylamino such as acetamido and benzamido, arylam o, guamdmo, imidazolyl, mdolyl, mercapto, alkylthio, arylthio (such as phenylthio) carboxy, carboxamido, carbo-alkoxy, or sulfonamide,
  • substituent is selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, such as phenoxy, ammo, di-alkylammo, acylamino such as acetamido and benzamido, arylammo, guamdmo, imidazolyl, indolyl, mercapto, alkylthio, arylthio (such as phenylthio) carboxy, carboxamido, carbo-alkoxy, or sulfonamide,-
  • R ll is H, -S0 2 -Ci-C 6 -alkyl, -S0 2 -Ci-C 6 -alkyl-substituted aryl, -S0 2 -aryl, -S0 2 -subst ⁇ tuted heteroaryl, -COR 9 , -C0 2 t- Bu, -C0 2 Bn, or -alkyl-substituted aryl wherein the substituent is selected from: hydrogen, C1-C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylamino, acylamino, thio, thioalkyl, carboxy, carboxamido or aryl;
  • R 12 is selected from: H, aryl, (Ci to C10)alkyl-, aryl (Ci to C6)alkyl-, C3 to C11 cycloalkyl, C3 to C10 alkylcarbonyloxyalkyl, C3 to C10 alkoxycarbonyloxyalkyl, C2 to C10 alkoxycarbonyl, C5 to C10 cycloalkylcarbonyloxyalkyl, C5 to C10 cycloalkoxycarbonyloxyalkyl, C5 to C10 cycloalkoxycarbonyl, aryloxycarbonyl, aryloxycarbonyloxy(Ci to C ⁇ alkyl)-, arylcarbonyloxy(Ci to C6 alkyl)-, C5 to C12 alkoxyalkylcarbonyloxyalkyl,
  • R 13 is H or C1 -C4 linear alkyl ;
  • R 15 is selected from:
  • R 16 is C 1 -C 4 alkyl, benzyl, or phenyl
  • R 17 and R 17a is independently selected from: H, C ⁇ -C ⁇ o alkyl,C2-C6 alkenyl, C4-C11 cycloalkylalkyl, and aryl(C ⁇ -C 6 alkyl) ;
  • Combinations of A, B and D, and/or variables are permissable only if such combinations result in stable compounds (as defined herein) .
  • A can be absent, -(CHR 6 ) m -, -0(CHR 6 ) m -,
  • B can be a bond or selected from -NH-, -NR 11 -, - NR ll - -0-, -S(0)p-(C ⁇ -C 5 )alkyl-NH-(C ⁇ -C 6 )alkyl-, (C ⁇ -C 6 )alkyl-NR 11 - (C ⁇ -C 6 ) alky- , -C ⁇ -C 6 -NH-aryl-, -0- (Ci-C ⁇ ) alkyl-, - (C ⁇ -C 6 )alkyl-O-aryl-, -S- (Ci-C ⁇ ) alkyl-, - (C ⁇ -C 6 )alkyl-S-aryl- , - (C ⁇ -C 6 )alkyl-, - (C ⁇ -C 6 )alkenyl-, - (C ⁇ -C 6 )alkynyl-, -CONH-, -CONR 11 , -NHCO-, -NR
  • D can be absent or an alkyl from 1 to 10 carbon atoms optionally terupted by 0, S or NR 6 , which include branched and cyclic and unsaturated alkyl groups and - (C ⁇ -C 6 ) -alkyl-aryl;
  • p can be 0, 1 or 2;
  • n is an integer from 1 to 5;
  • W is -0-, -S(0)p- or -NR 10 -,-
  • Y is selected from: -CONR 10 -, -NR 10 CO-, -S0 2 NR 10 -, -NR 10 S0 2 -, a peptide bond mimic, a 5 membered heterocyclic ring saturated, unsaturated or partially unsaturated containing from 1 to 4 heteroatoms selected from N,0 or S,
  • Preferred compounds of the present invention are compounds of formula II where;
  • X is selected from CH 2 , NH, S and 0;
  • the size of the macrocycle encompased formula I by -A-B-D-C (R 2 ) (R 3 ) -Y-C (R 1 ) -X-C (U) (R 4 ) - be connected by no less than 11 atoms and no more than 22 atoms to form the cycle.
  • U is selected from: -CONHOH, -C(0)NH0R 12 ⁇ -C0 2 H and common prodrug derivatives;
  • R 1 is selected from-. H, -(C 0 -C 6 )alkyl- ⁇ (O)p-(C ⁇ -C 6 )alkyl,
  • substituent is selected from; hydrogen, C1-C5 alkyl, hydroxy, halo, alkoxy, amino, mono-alkylammo, di-alkylammo, acylammo, thio, thioalkyl, carboxy, carboamido or aryl;
  • R 2 is selected from H, -C0 2 R 5 , -CONR 6 R 5 , -CONR 6 (OR 5 ), -alkyl, -alkylaryl, -alkylheteroaryl, -alkylheterocyclic, -aryl, -heteroaryl or -heterocyclic which is substituted with one or more substituents selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, (such as phenoxy) , ammo, mono-alkylammo, di- alkylamino, acylamino (such as acetamido and benzamido) , arylammo, guamdmo, N-methyl imidazolyl, imidazolyl, mdolyl, mercapto, lower alkylthio, arylthio (such as phenylthio) , carboxy, sulfona ido, carbox
  • R 3 and R 4 are H
  • P 5 is selected from: - (CHR 1 Y) n -R 9 - -C(R 7 R 8 ) n -W-C(R 7 R 8 ) m -R 9 ,
  • R 7 R 8 m -subst ⁇ tuted heterocyclic, wherein the substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylammo, thio, thioalkyl, carboxy, carboxamido or aryl;
  • R 6 is selected from:
  • R 5 and R 6 may form a 3 to 8 membered ring optionally unsaturated containing from 1 to 3 heteroatom ⁇ selected from -0, -NR 6 , -S(0)p, or an acyl group, optionally fused to an aryl ring;
  • R 7 and R 8 may be selected independently from:
  • substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylam o, thio, thioalkyl, carboxy, carboamido or aryl, optionally containing -0-, -S(0)p, -NR 6 , optionally fused to a substituted aryl ring, wherein the substituent is selected from,- hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylam o, thio, thioalkyl, carboxy, carboxamido or aryl; R 9 is H, alkyl, cycloalkyl, 5 or 6 membered ring optionally containing from 1 to 2 N, 0 or S(0)p, optionally substituted with
  • R 10 is H or an optionally substituted alkyl group
  • R 11 is hydrogen, alkyl of from 1 to 6 C atoms which include branched, cyclic and unsaturated alkyl groups, substituted alkyl; wherein the substituent is selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, such as phenoxy, ammo, di-alkylammo, acylamino such as acetamido and benzamido, arylammo, guamdmo, imidazolyl, dolyl, mercapto, loweralkylthio, arylthio (such as phenylthio) carboxy, carboxamido, carbo-alkoxy, and sulfonamide;
  • substituent is selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, such as phenoxy, ammo, di-alkylammo, acylam o such as acetamido and benzamido, arylammo, guamdmo, imidazolyl, mdolyl, mercapto, loweralkylthio, arylthio (such as phenylthio) carboxy, carboxamido, carbo-alkoxy, and sulfonamide;
  • R lla is H, -S0 2 -C ⁇ -C 6 -alkyl, -S0 2 -Ci-C 6 -alkyl- substituted aryl, -S0 2 -aryl, -S0 2 -substituted heteroaryl, -COR 9 , -C0 t-Bu, -C0 2 Bn, wherein the substituent is selected from: hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylamino, acylammo, thio, thioalkyl, carboxy, carboxamido or aryl;
  • R 12 is selected from: H , aryl , (Ci to Ci o ) alkyl - , aryl ( Ci to C6 ) lkyl- ,
  • R 13 is H or C 1 -C 4 linear alkyl
  • R 16 is C1-C4 alkyl, benzyl, or phenyl
  • R 17 and R 17a is independently selected from: H, C1-C1 0 alkyl,C2-C6 alkenyl, C4-C11 cycloalkylalkyl, and aryl(C ⁇ -C 6 alkyl) ;
  • Combinations of A, B and D, and/or variables are permissable only if such combinations result in stable compounds (as defined herein) .
  • A can be absent, -(CHR 6 ) m -, -0(CHR 6 ) m -,
  • B can be a bond or selected from -NH-, -NR 11 -, -NR lla -, -0-, -S(0)p-Ci-C 6 alkyl-NH-Ci-C 6 alkyl-, Ci-C ⁇ alkyl-NRH-Ci- C 6 alky-, C ⁇ -C 6 -NH-aryl-, -0-C ⁇ -C 6 alkyl- , Ci-C ⁇ alkyl-O- aryl-, -S-Cl-C6alkyl- , Cl-C6alkyl-S-aryl- , C ⁇ -C 6 alkyl- , C ⁇ -C 6 alkenyl-, C ⁇ -C 6 alkynyl- , -CONH- , -CONR 11 , -NHCO- , -NR l lCO-, -0C0-, -COO-, -0C02-, -R- ⁇ NCONR 11 - , HNCON
  • D can be absent or an alkyl of from 1 to 6 carbon atoms which include branched and cyclic and unsaturated alkyl groups or - (Ci-C ⁇ jalkyl-aryl;
  • p can be 0, 1 or 2;
  • n is an integer from 0 to 3 ;
  • n is an integer from 1 to 4.
  • Y is selected from: -CONR 10 -, -NR 10 CO-, -S0 2 NR 10 -, -NR 10 S0 2 -, a peptide bond mimic, a 5 membered heterocyclic ring saturated, unsaturated or partially unsaturated containing from 1 to 4 heteroatoms selected from N,0 or S,
  • X is selected from CH , NH, S and 0;
  • U is selected from; -C0 2 H, -C0 2 R 12 and common prodrug derivatives;
  • U is selected from: -CONHOH, -C(0)NH0R 12 , -C0 H, and common prodrug derivatives;
  • R 1 is selected from:
  • alkyl-0- (C 0 -C 6 ) alkyl-aryl alkyl of from 1 to 20 carbon atoms which include branched, cyclic and unsaturated alkyl groups, substituted alkyl wherein the substituent is selected from; hydrogen, halo, hydroxy, alkoxy, aryloxy, (such as phenoxy) , ammo, mono- alkylammo, di-alkylammo, acylammo (such as acetamido and benzamido) , arylammo, guamdmo, N- methyl imidazolyl, imidazolyl, mdolyl, mercapto, alkylthio, arylthio (such as phenylthio) , carboxy, carboxamido, carbo alkoxy, or sulfonamido,
  • substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylam o, thio, thioalkyl, carboxy, carboamido or aryl;
  • R 2 is selected from H, -C0 2 R 5 , -CONR 6 R 5 , -CONR 6 (OR 5 ), -alkyl, -alkylaryl, -alkylheteroaryl, -alkylheterocyclic, -aryl, -heteroaryl or -heterocyclic which is substituted with one or more substituents selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, (such as phenoxy) , ammo, mono-alkylamino, di- alkylammo, acylamino (such as acetamido and benzamido) , arylammo, guamdmo, N-methyl imidazolyl, imidazolyl, mdolyl, mercapto, lower alkylthio, arylthio (such as phenylthio) , carboxy, sulfonamide carboxamido, or
  • R 3 and R 4 are H
  • R 5 is selected from:
  • R 6 is selected from:
  • R 5 and R 6 may form a 3 to 8 membered ring optionally unsaturated containing from 1 to 3 heteroatoms selected from -0, -NR 6 , -S(0)p, or an acyl group, optionally fused to an aryl ring;
  • R 7 and R 8 may be selected independently from:
  • substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alky1amino, di-alkylammo, acylamino, thio, thioalkyl, carboxy, carboamido or aryl, optionally containing -0-, -S(0)p, -NR 6 , optionally fused to a substituted aryl ring, wherein the substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylammo, thio, thioalkyl, carboxy, carboxamido or aryl;
  • P 9 is H, alkyl, cycloalkyl, 5 or 6 membered ring optionally containing from 1 to 2 N, 0 or S(0)p, optionally substituted with -OH, -0- (C ⁇ -C 6 )alkyl, -O-acyl-alkyl, NHR 10 , or aryl;
  • R 10 is H or an optionally substituted alkyl group
  • R 11 hydrogen, alkyl of from 1 to 6 C atoms which include branched, cyclic and unsaturated alkyl groups, substituted lower alkyl; wherein the substituent is selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, such as phenoxy, ammo, di-alkylammo, acylamino such as acetamido and benzamido, arylammo, guamdmo, imidazolyl, mdolyl, mercapto, loweralkylthio, arylthio (such as phenylthio) carboxy, carboxamido, carbo-alkoxy, and sulfonamide;
  • alkyl-substituted aryl wherein the substituent is selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, such as phenoxy, ammo, di-alkylamino, acylammo such as acetamido and benzamido, arylammo, guamdmo, imidazolyl, mdolyl, mercapto, loweralkylthio, arylthio (such as phenylthio) carboxy, carboxamido, carbo-alkoxy, and sulfonamide;
  • R ll is H, -S0 2 - (C ⁇ -C 6 ) alkyl, -S0 - (Ci-C ⁇ )alkyl substituted aryl, -S0 2 -aryl, - ⁇ 0 2 -substituted heteroaryl, -COR 9 , -C0 2 t- Bu, -C0 Bn, wherein the substituent is selected from: hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylamino, di-alkylamino, acylammo, thio, thioalkyl, carboxy, carboxamido or aryl;
  • R 12 is selected from: H, aryl, (Ci to Cio)alkyl-, aryl - (Ci to C ⁇ )alkyl, C3 to C11 cycloalkyl, C3 to Cio alkylcarbonyloxyalkyl, C3 to Cio alkoxycarbonyloxyalkyl, C2 to Cio alkoxycarbonyl, C5 to Cio cycloalkylcarbonyloxyalkyl, C5 to Cio cycloalkoxycarbonyloxyalkyl, C5 to Cio cycloalkoxycarbonyloxyalkyl, C5 to Cio cycloalkoxycarbonyl, aryloxycarbonyl, aryloxycarbonyloxy(Ci to C6 alkyl) , arylcarbonyloxy (Ci to C ⁇ alkyl) , C5 to C12 alkoxyalkylcarbonyloxyalkyl, [5- (C1-C5 alkyl) -1, 3-dio
  • R 13 is H or C1-C 4 linear alkyl
  • R 15 is selected from:
  • R 16 is C 1 -C 4 alkyl, benzyl, or phenyl
  • A can be;
  • B can be a bond or selected from -NH-, -NR 11 -, -NR lla -, -0-, -S(0)p-Ci-C 6 alkyl-NH-Ci-C 6 alkyl-, C ⁇ -C 6 alkyl-NR 1t -C ⁇ - C 6 alky-, Ci-C ⁇ -NH-aryl-, -0-C ⁇ -C 6 alkyl- , Ci-C 6 alkyl-0- aryl-, -S-Cl-C6alkyl- , Cl-C6alkyl-S-aryl- , C ⁇ -C 6 alkyl- , C ⁇ -C6alkenyl-, C ⁇ -C 6 alkynyl- , -CONH- , -CONR 11 , -NHCO- , -NR 1:l CO-, -OCO-, -COO-, -OC02-, -Rii CONR 11 - , H CONH- ,
  • D is -(CH 2 )m-
  • p can be 0 , 1 or 2 ;
  • n is an integer from 0 to 3;
  • n is an integer from 1 to 4.
  • Y is selected from: -CONR 10 -, -NR 10 CO-, -S0 2 NR 10 -, -NR 10 SO 2 -, a peptide bond mimic, a 5 membered heterocyclic ring saturated, unsaturated or partially unsaturated containing from 1 to 4 heteroatoms selected from N,0 or S, w th the proviso that the size of the macrocycle encompased in formula I by -A-B-D-C (R 2 ) (R 3 ) -Y-C (R 1 ) -C (U) (R )-, be connected by no less than 11 atoms and no more than 22 atoms to form the cycle.
  • R 1 is selected from: H,
  • substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylamino, thio, thioalkyl, carboxy, carboa ido or aryl;
  • R 5 is selected from:
  • R 6 is selected from:
  • R 5 and R 6 may form a 3 to 8 membered ring optionally unsaturated containing from 1 to 3 heteroatoms selected from -0, -NR 6 , -S(0)p, or an acyl group, optionally fused to an aryl ring;
  • R 7 and R 8 may be selected independently from:
  • substituent is selected from; hydrogen, C 1 -C 5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylamino, acylammo, thio, thioalkyl, carboxy, carboamido or aryl, optionally containing -0- , -S(0)p, -NR 6 , optionally fused to a substituted aryl ring, wherein the substituent is selected from; hydrogen, C1-C5 alkyl, hydroxy, halo, alkoxy, ammo, mono-alkylammo, di-alkylammo, acylammo, thio, thioalkyl, carboxy, carboxamido or aryl;
  • R 9 is H, alkyl, cycloalkyl, 5 or 6 membered ring optionally containing from 1 to 2 N, 0 or S(0)p, optionally substituted with -OH, -0- (Ci-C ⁇ alkyl, -O-acyl-alkyl, NHR 10 , or aryl;
  • R 10 is H or an optionally substituted alkyl group
  • R 11 is hydrogen, alkyl of from 1 to 6 C atoms which include branched, cyclic and unsaturated alkyl groups, substituted lower alkyl; wherein the substituent is selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, such as phenoxy, amino, di-alkylammo, acylammo such as acetamido and benzamido, arylammo, guamdmo, imidazolyl, mdolyl, mercapto, loweralkylthio, arylthio (such as phenylthio) carboxy, carboxamido, carbo-alkoxy, and sulfonamide; - (C ⁇ -C )alkyl-aryl, - (C ⁇ -C 8 )alkyl-subst ⁇ tuted aryl, wherein the substituent is selected from: hydrogen, halo, hydroxy, alkoxy, aryloxy, such as phen
  • n is an integer from 0 to 5;
  • n is an integer from 1 to 5;
  • p can be 0, 1 or 2;
  • W is -0-, S(0)p or NR 10 ;
  • Y is selected from: -CONR 10 -, -NR 10 CO-, -S0 2 NR 10 -, -NR 10 SO 2 -, a peptide bond mimic, a 5 membered heterocyclic ring saturated, unsaturated or partially unsaturated containing from 1 to 4 heteroatoms selected from N,0 or S,
  • Most preferred compounds of the present invention include compounds of formula I, or a pharmaceutically acceptable salt or prodrug form thereof, selected from the following:
  • the compounds above are useful as inhibitors of metalloproteinases, including aggrecanase and TNF-C, and are useful for the treatment of rheumatoid arthritis, osteoarth ⁇ tis and related inflammatory disorders, as described previously. These compounds inhibit the production of TNF animal models and are useful for the treatment of diseases mediated by TNF.
  • the present invention also provides methods for the treatment of osteo- and rheumatoid arthritis and related disorders as described previously, by administering to a host a pharmaceutically or therapeutically effective or acceptable amount of a compound of formulas (I to IV) as described above.
  • therapeutically effective amount it is meant an amount of a compound of the present invention effective to inhibit the target enzyme or to treat the symptoms of osteo- or rheumatoid arthritis or related disorder, in a host.
  • the compounds of the present invention can also be administered in combination with one or more additional therapeutic agents.
  • Administration of the compounds of Formulas I-IV of the invention in combination with such additional therapeutic agent may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each.
  • a lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.
  • therapeutically effective amount it is meant an amount of a compound of Formulas I-IV that when administered alone or in combination with an additional therapeutic agent to a cell or mammal is effective to inhibit the target enzyme so as to prevent or ameliorate the lnflamatory disease condition or the progression of the disease.
  • administered in combination or “combination therapy” it is meant that the compound of Formulas I-IV and one or more additional therapeutic agents are administered concurrently to the mammal being treated.
  • each component may be administered at the same time or sequentially m any order at different points in time.
  • each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect.
  • stable compound or “stable structure” is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent .
  • any variable occurs more than one time in any constituent or in Formulas I-IV (or any other formula herein)
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • said group may optionally be substituted with up to two R 5 and R 5 at each occurrence is selected independently from the defined list of possible R 5 .
  • combinations of substituents and/or variables are permissible only if such combinations result m stable compounds.
  • substituent when a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of Formulas I-IV then such substituent may be bonded via any atom in such substituent.
  • substituent when the substituent is piperazmyl, piperidmyl, or tetrazolyl, unless specified otherwise, said piperazmyl, piperidmyl, tetrazolyl group may be bonded to the rest of the compound of Formula I via any atom in such piperazmyl, piperidmyl, tetrazolyl group.
  • stable compound or stable structure it is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • substituted means that any ⁇ one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • 2 hydrogens on the atom are replaced.
  • alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (for example, “C 1 -C 10 " denotes alkyl having 1 to 10 carbon atoms) ,- in addition lower alkyl defines branched and/or unbranched alkyl chain of from 1 to 8 C atoms;
  • alkoxy represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge;
  • cycloalkyl is intended to include saturated ring groups, including mono-,b ⁇ - or polycyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclo
  • alkenyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur m any stable point along the chain, such as ethenyl, propenyl and the like; and "alkynyl” is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl and the like.
  • Alkylcarbonyl is intended to include an alkyl group of an indicated number of carbon atoms attached through a carbonyl group to the residue of the compound at the designated location.
  • Alkylcarbonyla mo is intended to include an alkyl group of an indicated number of carbon atoms attached through a carbonyl group to an ammo bridge, where the bridge is attached to the residue of the compound at the designated location.
  • Alkylcarbonyloxy is intended to include an alkyl group of an indicated number of carbon atoms attached to a carbonyl group, where the carbonyl group is attached through an oxygen atom to the residue of the compound at the designated location.
  • alkylene alkenylene
  • phenylene phenylene
  • alkylene alkenylene
  • phenylene phenylene
  • alkylene alkenylene
  • phenylene phenylene
  • Halo or "halogen” as used herein refers to fluoro, chloro, bromo and lodo; and "counterion” is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate and the like.
  • carbocycle or “carbocyclic residue” or “carbocyclic ring system” is intended to mean any stable 3- to 7- membered monocyclic or bicyclic or 7- to 14-membered bicyclic or tricyclic or up to 26-membered polycyclic carbon ring, any of which may be saturated, partially unsaturated, or aromatic.
  • carbocyles include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, biphenyl, naphthyl, mdanyl, adamantyl, or tetrahydronaphthyl (tetralm) .
  • aryl or “aromatic residue” is intended to include phenyl or naphthyl as well as commonly referred to "heterocycle” or “heteroaryl” or “heterocyclic” compounds; the term “arylalkyl” represents an aryl group attached through an alkyl bridge.
  • heterocycle or “heteroaryl” or “heterocyclic” is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10- membered bicyclic ring which may be partially unsaturated, or aromatic, and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen may optionally be quatermzed, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • a heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results m a stable structure.
  • the aromatic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • aryl groups include, but are not limited to, pyridyl (pyridmyl), pyrimidinyl, furanyl (furyl), thiazolyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, benzothiophenyl, mdolyl, mdolenyl, qumolmyl, lsoqumolmyl, benzimidazolyl, piperidmyl, 4-p ⁇ per ⁇ donyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolmyl, tetrahydrofuranyl, tetrahydroquinolmyl, tetrahydr
  • aryl is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic ring which may be partially unsaturated, or aromatic, and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen may optionally be quatermzed, and including any bicyclic group in which any of the above- defined heterocyclic rings is fused to a benzene ring.
  • a heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • aryl groups include, but are not limited to, pyridyl (pyridinyl), pyrimidinyl, furanyl (furyl), thiazolyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, benzothiophenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-p ⁇ peridonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolmyl, tetrahydrofuranyl, tetrahydroquinolmyl, tetrahydroisoqumolinyl, decahydroquinolinyl or octahydroisoqumolmyl, azo
  • ammo acid as used herein means an organic compound containing both a basic ammo group and an acidic carboxyl group. Included withm this term are natural ammo acids, modified and unusual ammo acids, as well as ammo acids which are known to occur biologically in free or combined form but usually do not occur in proteins. Included within this term are modified and unusual ammo acids, such as those disclosed in, for example, Roberts and Vellaccio (1983) The Peptides. 5: 342-429, the teaching of which is hereby incorporated by reference.
  • Modified or unusual ammo acids which can be used to practice the invention include, but are not limited to, D-ammo acids, hydroxylysme, 4-hydroxyprolme, an N-Cbz-protected ammo acid, ornithine, 2, 4-d ⁇ am ⁇ nobutyr ⁇ c acid, homoargmme, norleucme, N-methylaminobutyric acid, naphthylalanine, phenylglycine, ⁇ -phenylprolme, tert-leucme, 4-am ⁇ nocyclohexylalanme, N-methyl-norleucine, 3 , 4-dehydroprolme, N,N-d ⁇ methylam ⁇ noglycme, N-methylammoglycme, 4-ammop ⁇ pe ⁇ d ⁇ ne-4-carboxyl ⁇ c acid, 6-ammocapro ⁇ c acid, trans-4- (ammomethyl) - cyclohexanecarboxylic acid, 2-,
  • amino acid residue means that portion of an amino acid (as defined herein) that is present in a peptide.
  • peptide as used herein means a compound that consists of two or more ammo acids (as defined herein) that are linked by means of a peptide bond.
  • peptide also includes compounds containing both peptide and non-peptide components, such as pseudopeptide or peptide mimetic residues or other non-ammo acid components. Such a compound containing both peptide and non-peptide components may also be referred to as a "peptide analog".
  • peptide bond means a covalent amide linkage formed by loss of a molecule of water between the carboxyl group of one ammo acid and the ammo group of a second ammo acid.
  • Prodrugs are considered to be any covalently bonded carriers which release the active parent drug according to Formula I-III m vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of the compounds of Formula I-III are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds.
  • Prodrugs include compounds of Formulas I-IV wherein hydroxyl, ammo, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, ammo, sulfhydryl, or carboxyl group respectively.
  • prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups m the compounds of Formulas I-IV, phosphate esters, dimethylglycme esters, ammoalkylbenzyl esters, ammoalkyl esters and carboxyalkyl esters of alcohol and phenol functional groups in the compounds of formula (I) and the like.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound of Formulas I-IV is modified by making acid or base salts of the compound of Formulas I-IV.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines? alkali or organic salts of acidic residues such as carboxylic acids and the like.
  • the pharmaceutically acceptable salts of the compounds of Formulas I-IV include the conventional non-toxic salts or the quaternary ammonium salts of the compounds of Formulas I-IV formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like,- and the salts prepared from organic acids such as acetic, propiomc, succi c, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfamlic, 2-acetoxybenzo ⁇ c, fumaric, toluenesulfonic, methanesulfomc, ethane disulfomc, oxalic, lsethio
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of Formula I-III which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
  • a base such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine, e.g., dibenzylethylenediamme, trimethylamme, piperidme, pyrrolldme, benzylamine and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.
  • a base such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium
  • an organic base such as an amine, e.g., dibenzylethylenediamme, trimethylamme, piperidme, pyrrolldme, benzylamine and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.
  • pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid, respectively, in water or m an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetomtrile are preferred.
  • nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetomtrile are preferred.
  • Lists of suitable salts are found m Remington's Pharmaceutical Sciences , 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
  • the compounds of the present invention can be prepared m a number of ways well known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.
  • novel compounds of this invention may be prepared using the reactions and techniques described in this section.
  • the reactions are performed m solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected.
  • all proposed reaction conditions including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled m the art.
  • the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.
  • a series of compounds of formula 21 are prepared by the methods outlined in Schemes 1-5.
  • a diprotected 2,3- diammopropiomc acid, 2,4-d ⁇ ammobutyr ⁇ c acid, ornithine or lysine (compound 1, Scheme 1) is converted to its corresponding amide 2 using a coupling agent such as BOP.
  • Coupling of 1 with a diammobenzene followed by reaction m acetic acid at 60 " C produces a benzimidazole analog 3.
  • 1 can also be converted to an aldehyde 4 which is reacted with ammonia and glyoxal trimer to give an imidazole analog 5.
  • Deprotection of the N°-Boc group of 2, 3 and 5 using an acid such as 4 N HCl in dioxane gave compound 6. Removal of the side chain protecting group of 2, 3 and 5 using hydrogenation afforded compound 7.
  • the formation of the macrocyclic ring of this series of compounds can be accomplished via two routes as described in schemes 3 and 4 below. Coupling of the intermediates 6 and 13 produces the intermediate 15. Hydrogenation followed by acid deprotection gives compound 16. Cyclization of 16 using a coupling agent such as BOP affords the macrocyclic intermediate 17. Alternatively, compound 17 can be synthesized by coupling 7 and 14 followed by deprotection and cyclization as described in Scheme 4. Saponification of 17 followed by reversed phase HPLC separation gives two isomers 20a and 20b. The final two products 21a and 21b were obtained by coupling 20a or 20b with 0- benzylhydroxyla ine hydrochloride followed by hydrogenation.
  • a side chain trifluoroacetyl protected 2,3-d ⁇ ammoprop ⁇ omc acid, 2,3- diammobutyric acid, ornithine or lysme 22 is coupled with an alkylamine followed by alkylation to give 23a.
  • the ammo acid derivative 22 can also be converted to a methyl ester which is alkylated to give 24. Removal of the TFA group of 24 followed by protection of the resulting amine using benzyl chloroformate affords compound 25. 25 can be converted to a benzimidazole derivative 23b or an imidazole derivative 23c.
  • the target compound 30 is obtained using the procedures described m Scheme 7 which are similar to those used for the synthesis of the first series of compounds 21 (Schemes 4-5 above) .
  • Another series of compounds of formula 43 are prepared by the methods outlined in Schemes 8-9 below.
  • a N- ⁇ Cbz- serine or homoserme is converted to its corresponding amide which is alkylated with ethyl bromoacetate to give 31.
  • a different starting material ⁇ -Boc-serme or homoserme is converted to a benzyl ester which is also alkylated with ethyl bromoacetate to give 32.
  • the benzyl ester of 32 is removed by hydrogenation to give 33 which can be converted to a benzimidazole derivative 34 or an imidazole derivative 35.
  • Deprotection of the Cbz group of 31 by hydrogenation or the Boc group of 34 and 35 using acid produces the intermediate 36.
  • Coupling of 47 with the acid component 8 gives the intermediate 48.
  • the nitro group is reduced using zinc in acetic acid/water and the t-butyl group is removed using 4 N HCl in dioxane.
  • Macrocyclization of 49 using BOP yields two isomers 50a and 50b which are separated on a silica gel column. Saponification of each isomer followed by coupling with hydroxyla me produces the target products 51a and 51b.
  • Reaction of the intermediate 38 with a triflate produces 58. Coupling of the acid component 58 with 57 yields 59.
  • the benzyl group of 59 is taken off by hydrogenation and the resulting alcohol is converted to a bromide using carbon tetrabromide and t iphenylphos h e.
  • Macroyclization of the resultant intermediate is carried out using potassium carbonate to give the cyclic product 60.
  • the t-butyl group is deprotected using TFA and the resulting carboxylic acid is converted to a hydroxamic acid by coupling with hydroxylamme to afforded the target product 61.
  • This invention also includes cyclic hydroxamates as described in scheme 29.
  • succmate 134 is coupled with L-lysine(ISP-Cbz) -NHMe to yield the amide 135.
  • the primary alcohol of 135 is oxidized to the acid 136 with RuCl 3 »H 2 0.
  • a macrocyclization affords the lactam 138.
  • the t-butyl ester of 138 is then converted to the acid 139.
  • This acid is coupled with BnO H 2 to give the protected hydroxamate 140. Hydrogenation of 140 provides the target hydroxamate 141.
  • This invention also includes compounds available by the methods described in Scheme 30 which allows for the simple variation of R 3 from the common intermediate 145a.
  • succmate 134 is coupled with L- lys ⁇ ne(N?-Cbz) -C0 2 Me to yield the amide 142.
  • the primary alcohol of 142 is oxidized to the acid 143 with RuCl 3 »H 2 0.
  • a macrocyclization affords the lactam 144.
  • the t-butyl ester of 144 is converted to the protected hydroxamate 145 under our standard protocol.
  • the methyl ester of 145 is hydrolyzed with LiOH.
  • the resulting acid 145a is manipulated to give a desired R 3 . Hydrogenation of 146 gives the target hydroxamate 147.
  • Scheme 31 depicts how a compound of this type is available from D-glutamic-N-Fmoc t-butyl ester or D-aspartic -N-Fmoc t-butyl ester through standard peptide chemistry. Standard BOP coupling of this material with 7 gives the amide 148.
  • the Fmoc group can be deprotected to the primary amine 149 followed by alkylation with a trifate to yield the secondary amine 150 (Kogan, T.P.; Somers, T.C.; Venuti, M.C. Te trahedron 1990, 46, 6623) .
  • Dual deprotection via hydrogenation affords the amino acid 151, which can be cyclized to give the macrolactam 152.
  • Simple deprotection with TFA provides the desired, cyclic amino carboxylate 153.
  • Scheme 32 depicts how a compound of this type is available from D-lysme-N-Fmoc t-butyl ester or D-ornithme-N-Fmoc t-butyl ester through standard peptide chemistry.
  • Standard BOP coupling of this material with L-glutamic-r ⁇ -Cbz methyl ester or L-aspartic-N" gives the amide 154.
  • Deprotection of the Fmoc group leads to the primary amine 155.
  • the primary amine can be alkylated as above with a triflate to give the secondary amine 156.
  • Dual deprotect via hydrogenation gives the amino acid 157.
  • Macrocycization can be performed using BOP to give lactam 158. Saponification of 158 followed by standard coupling with BOP and methylamine gives the amide 159. Simple deprotection with TFA affords the cyclic amino carboxylate 160.
  • Scheme 33 depicts how a compound of this type is available from D-Aspartic-N-Boc- ( ⁇ ) -t-butyl ester or D-glutamic-N-Boc- ( ⁇ ) -t-butyl ester through standard peptide chemistry.
  • the ⁇ -acid is converted into an aldehyde 161 using e reb chemistry (Wernic, D.; DiMaio, J.; Adams, J. J. Org. Chem . 1989, 54, 4224) .
  • This material can be converted into the olefm 162 via a ittig 2 reaction with 4-carbomethoxybenzyl triphenylphosphonium bromide (Lancaster) .
  • a serme amide is coupled with 163 to make the ester 164.
  • the Boc protected am e of 164 is deprotected with HCl to provide the primary amme 165.
  • the primary amme can be alkylated as above with a triflate to give the secondary amme 166.
  • Dual deprotect via hydrogenation gives the ammo acid 167.
  • Macrocycization can be performed to give lactam 168. Simple deprotection with TFA affords the cyclic ammo carboxylate 169.
  • Scheme 34 depicts how a compound of this type is available from D-homoserine-N-Fmoc- ( ⁇ )-t-butyl ester through standard peptide chemistry.
  • the primary alcohol of the serme derivative can be coupled to the phenol of a tyrosme derivative via a Mitsunobu reaction to give 170 (Hughes, D.l.
  • Scheme 35 depicts how a compound of this type is available from L-glutamic-N-Cbz- ( ⁇ ) -methyl ester or L-aspartic-N-Cbz- ( ⁇ ) -methyl ester through standard peptide chemistry.
  • This material can be coupled to 2-N-Boc-aminoethanol with DCC and DMAP to yield the ester 176.
  • Functional group manipulation leads to the acid followed by the amide 177 by standard chemistry.
  • the Boc group of 177 is then removed with TFA to give 178.
  • This material can be coupled to D-glutamic-N-Fmoc- ( ⁇ )-t- butyl ester or D-aspartic-N-Fmoc- ( ⁇ )-t-butyl ester to give the amide 179.
  • the Fmoc is removed with diethylamine to reveal the primary amme 180. As above, this primary amine can be alkylated with a triflate to give 181. Hydrogenation and macrocyclization of this ammo acid with BOP affords the lactam 182. Simple deprotection with TFA gives the desired am o carboxylate 183.
  • Scheme 36 depicts how a compound of this type is available from L-aspartic-N-Fmoc- ( ⁇ ) -t-butyl ester or L-glutamic-N-Fmoc- ( ⁇ ) -t-butyl ester through standard peptide chemistry.
  • the acid can be converted 2 into the aldehyde 184 using Wemreb chemistry.
  • This aldehyde can participate in a reductive ammation with a lysine derivative to produce the am e 185.
  • the Fmoc is removed with diethylamme to give primary amime 185.
  • the primary amine 185 can be alkylated with a t ⁇ fate to provide the secondary amme 188.
  • Dual deprotection of the material via hydrogenation yields the ammo acid 189. Macrocyclization of this ammo acid with BOP affords the lacta 188. Simple deprotection with TFA gives the desired ammo carboxylate 189.
  • Another series of compounds of formula 205 are synthesized as shown in Scheme 39.
  • the succinate 134 is coupled with L-glutamate( ⁇ -C0 2 Bn) N-methyl amide to afford the amide 200.
  • the compound is cyclized under the Mitsunobu conditions to yield 202.
  • the t-butyl ester of 202 is converted to the acid 203.
  • This acid is coupled with BnONH 2 to give the protected hydroxamate 204.
  • Hydrogenation of 204 provides the target hydroxamate 205.
  • Cyclic ureas of formula 3019, where Z is a N-alkyl amide, an imidazole or a benzimidazole could be prepared as shown in scheme 43 below.
  • An intermediate 3015 is obtained by reaction of 8 with a a-keto-ammocarboxylic ester . Removal of the chiral auxiliary is followed by the standard peptide coupling with a lysine or ornithine derivative 6 to af ford 3017. Hydrogenolysis of the protecting groups and treatment with CDI yields cyclic urea 3018 . Conversion to the final compound 3019 is done in a manner analogous to that described in scheme 40 .
  • Cyclic lactams of formula 3023 where Z is a N-alkyl amide, an imidazole or a benzimidazole could be prepared as depicted in scheme 44.
  • the intermediate 3015 is hydrogenated to give the amine 3019.
  • Coupling of 3019 with an aspartic acid or a glutamic acid derivative under standard peptide coupling conditions affords 3020.
  • Removal of chiral auxiliary and hydrogenolysis afford amino acid 3021.
  • Macrocyclization produces cyclic lactam 3022, which is converted to the desired compound 3023 using conditions described in scheme 40.
  • the compounds of the present invention can be prepared in a number of ways well known to one skilled m the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known m the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated m their entirety herein by reference.
  • novel compounds of Formula I may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Not all compounds of Formula I falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.
  • the reaction was stirred 10 minutes at -78 °C, 15 minutes in a room temperature water bath, then for 15 minutes at -78°C again, followed by quench with the rapid addition of methanol.
  • the reaction mixture was concentrated to -1/4 its origional volume under reduced pressure and the resulting material was dissolved m 200 ml of ethyl acetate and washed with a mixture of 70 mL of IN HCl and 100 grams of ice.
  • the aqueous was extracted 2 times with ethyl acetate.
  • the combined organic fractions were washed with a solution of 3.5 grams of KF dissolved 100 mL of water and 15 mL of 1 N HCl (pH 3-4) .
  • the resulting material was triterated 4 times with a mixture of 1:1:2 ethyl acetate:hexane:ether to afford 1.4 g of product.
  • the mothor liquor was concentrated and the resulting material was chromatographed on silica gel elutmg with a gradient of 25-90% ethyl acetate/hexane affording another 1.05 grams of product for a combined yield of 81%.
  • Example 20 2S.5R, 6S-3-aza-4-oxo-10-oxa-5- ⁇ sobutvl-2- r f3- ⁇ m ⁇ dazolvl)propvlcarboxam ⁇ do1-fl01paracvclophane-6-N- hvdroxvcarboxamide:
  • Example 41 25. 5R, 6S-3-aza-4-oxo-10-oxa-5- ⁇ sobutvl-2- (2- lmidazolvD- f101paracyclophane-6-N-hvdroxvcarboxamide:
  • N-methyl amide of l(k) was prepared as described previously to give 50(a) .
  • Example 61 2S. 5R. 6S-3-aza-4-oxo-10-oxa-5- ⁇ sobutv1 -7 - ( ⁇ lvcme-N-methvlam de)-riQ1paracvcloPhane-6-N- hvdroxvcarhoxamide:
  • Example 63 2S. 5R. 6S-3-aza-4-oxo-10-oxa-5- ⁇ sobutvl-2- (L- alan ⁇ ne-N-methvlam ⁇ de)-ri0l aracvclophane-6-N- hvdroxvcarhnxa de:
  • the mam band was removed, pulverized and rinsed with 150 mL of 10 % MeOH/CHCl3 affording 20 mg of the desired product.
  • M+H 477.
  • Example 65 2S. 5R, 6S-3-aza-4-oxo-10-oxa-5- ⁇ sobutyl-2- - al mne-N-methvlamido) - r101paracyclophane- -N- hvdroxycarboxamide:
  • Example 70 28. 5R. 6S-3-aza-4-oxo-10-oxa-5-isobutv1 -2- (T,- (0-methvl)t ⁇ rosine-N-methvlamido)-f101paracyclophane-6-N- hydroxvcarboxamide:
  • Example 72 2S. 5R. 6S-3-aza-4-oxo-10-oxa-5-isnbu vl-2- (beta-alanine-N-methvl carboxamido) -[101paracvclophane-6-N- hvdroxvcarhnxamid :
  • Example 75 2S. 5R. 6S-3-aza-4-oxo-l O-oxa-5- ⁇ sobutvl -2- (L- 0-terf.buf.vl )serme-N-methylamide) - ⁇ 101paracyclophane-6-N- hvdrox ⁇ carboxamid :
  • Example 77 28.5R.6S-3-aza-4-oxo-10-oxa-5- ⁇ sobutyl-2- ⁇ - (O- tert-butyl) serine-N-methylairu.de1 - riOlparacvclophane-6-N- hydroxycarboxamide:
  • Example 90 2S.5R.6S-3-aza-4-oxo-10-oxa- - ⁇ sobutvl-2- (L- lvsme-N-methvlamide)-fl0lparacvclophane-6-N- hvdroxvc rhoxam de-.
  • Example 106 2S. R.6S-3-aza-4-oxo-10-oxa-5- ⁇ sobutvl-2- ⁇ 2 - (4-am ⁇ nosulfonvlphenvl) thylcarboxamido1 - [101 oaracvclophane-6-N-hvdroxycarboxam ⁇ de:
  • Example 120 2S. R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (carboxvmethvl) - Q01paracvclophane-6-N-hvdroxvcarboxam de
  • Example 126 2S ⁇ 5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- ( 12 - methoxvlethvloxy)carboxvl)-ri0lparacvclophane-6-N- hvdroxvcarboxa ide
  • Example 128 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexyl-2- ( (2- phenvlethvloxv)carboxy) - riOlparacvclophane-6-N- hvdroxvcarboxamide
  • Example 132 28.5R.6S-3-aza-4-oxo-10-oxa-5-hexv1 -2- (1 - f ⁇ - methylcarboximidoimethvlcarboxvl) - flOloaracvclophane-6-N- hvdroxvcarboxamide
  • Example 139 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (3- (1- imidazolvl)propvlcarboxamido)-ri0lDaracvclophane-6-N- hydrpxycarbQxamjde
  • Example 139.TFA 2S. R.6S-3-aza-4-oxo-l0-oxa-5-hexvl-2- (3- (l- ⁇ midazolyl)propvlcarboxamido) - f 01paracyclophane-6-N- hvdroxvcarboxamide trifluoroacetate
  • Example 146 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (4- methvIniperaz ⁇ n-l-vl)- ⁇ l aracvcl ⁇ Phane-6-N- hvdroxvcarboxamide
  • Example 156 2S.5R. S-3-aza-4-oxo-10-oxa-5-hexvl-2- (2- (N- methvlammosulfonyl) ethyl arboxamido)- riOlparacyclophane-6- N-hvdroxvcarhox ⁇ m p
  • Example 157 2S. R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- I A- fN- methvlaminn. ⁇ nlfonvDbutvlcarboxamido)- ⁇ 101paracyclophane-6- N-nvdroxvcarboxamide
  • 212(a) (35.2 mg, 0.0689 mmol) was reacted with 1, 4-diammobutane (84.6 mg, 14 equiv.) and then methanesulfonyl chloride (0.186 mL, 35 equiv.) to give the desired coupling product (24.2 mg, 53%).
  • Hydrogenolysis of the coupling product (24.0 mg, 0.0364 mmol) gave the hydroxamate (20.0 mg, 97%) .
  • ESI-MS (M+H) + calcd 569.3, found 569.5.
  • Example 158 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (cvclohexvlcarboxamido) - ri01paracvclophane-6-N- hvdroxvcarboxamide
  • Example 159 2S, 5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (2- (N- methvlaminosulfonvKhexvllcarboxamido) - flOlparacvcloohane- 6-N-hvdroxvcarboxamide
  • Example 165 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (L- orn ⁇ th ⁇ ne-N-methvlamide)- f101paracyclophane-6-N- hvdroxvcarboxamide hydrochloride
  • Example 182 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (L- alanme-N-methylamide) - riOlparacvclophane-6-N- hvdroxvcarboxamide
  • Example 184 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- fn- alanme-N-methvlam ⁇ de) - r i 1 paracvclophane-6-N- hvdroxvcarboxamide
  • 212(a) (40.8 mg, 0.080 mmol) was reacted with D-alanme-N-methylamide (12.2 mg, 1.5 equiv.) to give the desired coupling product (39.0 mg, 82%) .
  • Hydrogenolysis of the coupling product (32.0 mg, 0.054 mmol) then gave the hydroxamate (27.9 mg, 100%) .
  • ESI-MS (M+H) + calcd 505.4, found 505.5.
  • Example 201 28.5R.6S-3-aza-4-oxo-l0-oxa-5-hexvl-2- (2- (hvdroxvcarbonvl) ethylcarboxamido) - r101paracyclophane-6-N- hvdroxvcarboxamide
  • Example 203 2S.5R.6S-3-aza-4-oxo-10-oxa-5-he ⁇ yl-2- (T.- ormthme(4-t-butoxvcarbonvl) carboxvmethvl) - fl01paracvclophane-6-N-hvdroxvcarboxam ⁇ de
  • Example 205 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (I.- orn ⁇ th ⁇ ne(4-t-buto ⁇ ycarbonvl)-N-methvlam ⁇ de)- 101paracyclophane-6-N-hvdroxvcarboxamide
  • Example 207 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (L- ornithinecarboxymethyl) - r101paracyclophane-6-N- hvdroxvcarboxamide hydrochloride
  • Example 211 28.5R, 6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (phenvlethvlcarboxamido) - 1101paracyclophane-6-N- hvdroxvcarboxamide
  • Example 212 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (hvdroxvcarboxyl) - rlOlparacvclophane-6-N-hvdroxvcarboxamide
  • Example 213 28.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (2- ( .4-d ⁇ methoxvphenvl)ethylcarboxamido) - riOlparacvclophane- 6-N-hvdroxvcarboxam ⁇ de
  • Example 215 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexyl-2- ( 2 - (4- morpholmo) thylcarboxamido) - f101paracyclophane-6-N- hvdroxvca boxarmde
  • Example 217 28.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- (3- 14- orphol o)oropvlcarboxamido) - I10lparacvclophane-6-N- hvdroxvcarboxamide hydrochloride
  • Example 224 2S. R.6S-3-aza-4-oxo-10-oxa-5-hexyl-2- (diphenyl thylcarboxam do) - ⁇ 101paracyclophane-6-N- hvdroxvc rboxamide
  • Example 225 2S.5R.6S-3-aza-4-oxo-10-oxa-5-hexvl-2- 12- (4- sulfonylaminophenyl) thylcarboxamido) - ⁇ 101paracyclophane-6- -hydroxycarboxamide .
  • Example 710 4S.7R.8S-5-aza-6-oxo-12-oxa-7- ⁇ sobutvl-2- (carboxymethyl ) - ⁇ 121paracyclophane-R-N-hvdroxvcarboxaimde
  • Example 710 4S, 7R, 8S-5-aza-6-oxo-12-oxa-7- ⁇ sobutyl-2- (carboxvmethvl) - f121 aracvclophane-8-N-hvdroxvcarboxam de
  • 869(b) To a solution of 869(a) (15.20 g, 27.28 mmol) and N «-Cbz-N ⁇ -methyl-L-lysme methyl ester HCl salt (11.22 g, 32.78 mmol) was added potassium carbonate (15 g, 109 mmol) and the mixture was heated at 50 'C for 1 hour. Insoluble material was filtered off and EtOAc was added. The solution was washed with 10% citric acid, brine, NaHC0 3 and br e, dried (MgS ⁇ 4 ) and concentrated. Purification on a silica gel column using 15% EtOAc/hexane gave an oily product (17.0 g, 91%) . ESI-MS: calcd M+K713.5; found 713.7.
  • 869(c) 869(b) (10.0 g, 14.02 mmol) was dissolved 30 mL MeOH and the solution was hydrogenated for 1 hour under atmospheric pressure using 10% Pd-C (1.0 g) as catalyst. The catalyst was filtered off and the solution was concentrated to give an oily product (6.8 g, 100%) .

Abstract

L'invention concerne des molécules macrocycliques qui inhibent les métalloprotéinases, y compris l'agrécanase, et la production du facteur de nécrose tumorale (TNF). En particulier, les composés en question inhibent les métalloprotéinases intervenant dans la dégradation des tissus, d'une part, et la libération du TNF, d'autre part. On décrit par ailleurs des compositions pharmaceutiques renfermant ces composés et un certain nombre de procédés relatifs à l'utilisation de ces composés pour le traitement des maladies inflammatoires.
EP96943497A 1995-11-14 1996-11-13 Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease Withdrawn EP0863885A2 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US668495P 1995-11-14 1995-11-14
US6684P 1995-11-14
US64690296A 1996-05-08 1996-05-08
US646902 1996-05-08
US74343996A 1996-11-01 1996-11-01
US743439 1996-11-01
PCT/US1996/018382 WO1997018207A2 (fr) 1995-11-14 1996-11-13 Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease

Publications (1)

Publication Number Publication Date
EP0863885A2 true EP0863885A2 (fr) 1998-09-16

Family

ID=27358171

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96943497A Withdrawn EP0863885A2 (fr) 1995-11-14 1996-11-13 Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease

Country Status (17)

Country Link
EP (1) EP0863885A2 (fr)
JP (1) JP2000502050A (fr)
CN (1) CN1202161A (fr)
BR (1) BR9611563A (fr)
CA (1) CA2237524A1 (fr)
CZ (1) CZ144798A3 (fr)
EE (1) EE9800115A (fr)
HR (1) HRP960533A2 (fr)
HU (1) HUP0201479A2 (fr)
IL (1) IL124366A0 (fr)
LV (1) LV12167B (fr)
MX (1) MX9803851A (fr)
NO (1) NO982185L (fr)
PL (1) PL326714A1 (fr)
SI (1) SI9620120A (fr)
SK (1) SK63498A3 (fr)
WO (1) WO1997018207A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838466B2 (en) 2001-12-20 2005-01-04 Schering Corporation Compounds for the treatment of inflammatory disorders

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9820B (en) * 1997-01-07 1998-07-02 Abbott Lab Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion
DE69925262T2 (de) 1998-03-31 2006-02-23 Bristol-Myers Squibb Pharma Co. Pharmazeutika zur bildgebung der angiogenischen krankheiten
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
AU4821899A (en) 1998-06-11 1999-12-30 Du Pont Pharmaceuticals Company A process for the preparation of macrocyclic metalloprotease inhibitors
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
AU2371400A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511648B2 (en) 1998-12-18 2003-01-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6649377B1 (en) 1999-05-10 2003-11-18 Syntex (U.S.A.) Llc Human aggrecanase and nucleic acid compositions encoding the same
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
DE122010000047I1 (de) 2001-06-26 2011-05-05 Amgen Fremont Inc Antikörper gegen opgl
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JPWO2005044780A1 (ja) * 2003-11-10 2007-05-17 杏林製薬株式会社 アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
EP2234608A2 (fr) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
WO2010132494A1 (fr) * 2009-05-11 2010-11-18 Ghosh Arun K Composés et méthodes utilisables dans le cadre du traitement du sida et des infections par le vih
HRP20220319T1 (hr) 2011-05-19 2022-05-13 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Makrociklički spojevi kao inhibitori protein kinaze
CN102276546B (zh) * 2011-05-31 2014-06-25 中国科学院广州生物医药与健康研究院 用作蛋白聚糖酶调节剂的化合物及其应用
CN108727293B (zh) * 2016-09-18 2021-05-11 广西师范大学 1，2，8-氧代二氮杂环壬-9-酮衍生物及其合成方法
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
US5427954A (en) * 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9718207A2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838466B2 (en) 2001-12-20 2005-01-04 Schering Corporation Compounds for the treatment of inflammatory disorders
US7034057B2 (en) 2001-12-20 2006-04-25 Schering Corporation Compounds for the treatment of inflammatory disorders
US7598242B2 (en) 2001-12-20 2009-10-06 Schering Corporation Compounds for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
WO1997018207A3 (fr) 1997-07-24
IL124366A0 (en) 1998-12-06
NO982185L (no) 1998-07-13
MX9803851A (es) 1998-09-30
LV12167A (lv) 1998-11-20
NO982185D0 (no) 1998-05-13
WO1997018207A2 (fr) 1997-05-22
BR9611563A (pt) 1999-03-02
SI9620120A (sl) 1999-06-30
CA2237524A1 (fr) 1997-05-22
HRP960533A2 (en) 1998-04-30
CZ144798A3 (cs) 1998-10-14
PL326714A1 (en) 1998-10-26
CN1202161A (zh) 1998-12-16
JP2000502050A (ja) 2000-02-22
EE9800115A (et) 1998-10-15
LV12167B (en) 1999-03-20
HUP0201479A2 (en) 2002-08-28
SK63498A3 (en) 1999-01-11

Similar Documents

Publication Publication Date Title
EP0863885A2 (fr) Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease
US5703092A (en) Hydroxamic acid compounds as metalloprotease and TNF inhibitors
WO1995029892A1 (fr) Derives d'acides hydroxamiques et d'acides amines et leur utilisation comme agents antiarthritiques
EP1397137B1 (fr) Derives d'hydantoine utilises comme inhibiteurs des metalloproteinases matricielles
US5691381A (en) Hydroxamic and carbocyclic acids as metalloprotease inhibitors
JP2002541138A (ja) マトリックスメタロプロテアーゼ、ＴＮＦ−α、およびアグレカナーゼの阻害剤としての新規アミド誘導体
US6455522B1 (en) Cyclic sulfonamide derivatives as metalloproteinase inhibitors
US6495548B1 (en) Lactam inhibitors of matrix metalloproteinases, TNF-α and aggrecanase
US6281352B1 (en) Macrocyclic compounds as metalloprotease inhibitors
US6620823B2 (en) Lactam metalloprotease inhibitors
US20030181438A1 (en) Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
US6642255B2 (en) 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
US6720329B2 (en) Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE)
AU1272697A (en) Novel macrocyclic compounds as metalloprotease inhibitors
KR19990067592A (ko) 메탈로프로테아제 억제제로서의 신규한 마크로사이클릭 화합물
HRP950259A2 (en) Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
LT98068A (lt) Nauji makrocikliniai junginiai kaip metaloproteazės inhibitoriai

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980424

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DUPONT PHARMACEUTICALS COMPANY

17Q First examination report despatched

Effective date: 20000609

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRISTOL-MYERS SQUIBB PHARMA COMPANY

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030225